Sunday, January 26, 2020

Sanofi & Alnylam conclude research & option phase of 2014 alliance

Sanofi and Alnylam have agreed to conclude the research and option phase of the companies’ 2014 RNAi therapeutics alliance in rare genetic diseases.

The material collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran will continue unchanged.

As part of this agreement, Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease through the end of IND-enabling studies.

Sanofi will be responsible for any potential further development or commercialisation of such asset.

If this product is approved, Alnylam will be eligible to receive tiered double-digit royalties on its global net sales.

“Our alliance with Alnylam has successfully brought one important medicine to patients with ATTR amyloidosis and it also has spawned a molecule that is in pivotal clinical trials for people with haemophilia,” said John Reed, Global Head of Research and Development at Sanofi.

“As we wrap up this phase of our program with Alnylam, we remain committed to advancing therapies for patients with rare diseases and rare blood disorders.”

News

Sanofi completes $2.5bn Synthorx acquisition

Sanofi completes $2.5bn Synthorx acquisition

Sanofi has completed its $2.5 billion acquisition of Californian biotech, Synthorx, less than two months after the deal was first announced. “The acquisition of Synthorx...
Pfizer Vaccines launches first Centre of Excellence

Pfizer Vaccines launches first Centre of Excellence

The University of Louisville has been named as Pfizer’s first ‘Centre of Excellence’, part of its Vaccine Division’s global programme of collaborations with academic...
Two-drug combo that halts cancer cell growth discovered

Two-drug combo that halts cancer cell growth discovered

A two-drug combination that halts the growth of cancer cells has been discovered by researchers at UT Southwestern Simmons Cancer Centre. The findings, published in...

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here